Filtered By:
Procedure: Transplants

This page shows you your search results in order of date.

Order by Relevance | Date

Total 224 results found since Jan 2013.

Evaluation of safety and efficacy of allogeneic adipose tissue-derived mesenchymal stem cells in pediatric bronchiolitis obliterans syndrome (BoS) after allogeneic hematopoietic stem cell transplantation (allo-HSCT)
CONCLUSIONS: AT-MSCs could be safely administered to our pediatric cases with BoS post-allo-HSCT. Considering their advanced stage of disease, their sub-optimal functional capacity due to steroid-induced complications, and COVID-19 infection post-treatment, we believe that AT-MSC therapy can have possible efficacy in the management of pediatric BoS. The conduction of further studies with larger sample sizes and more frequent injections is prudent for further optimization of AT-MSC therapy against BoS. Trial registration Iranian Registry of Clinical Trials (IRCT), IRCT20201202049568N2. Registered 22 February 2021, https://e...
Source: Cell Research - September 19, 2023 Category: Cytology Authors: Rashin Mohseni Pouya Mahdavi Sharif Maryam Behfar Mohammad Reza Modaresi Rohola Shirzadi Mahta Mardani Leila Jafari Fahimeh Jafari Zeynab Nikfetrat Amir Ali Hamidieh Source Type: research

Cutting-edge regenerative therapy for Hirschsprung disease and its allied disorders
AbstractHirschsprung disease (HSCR) and its associated disorders (AD-HSCR) often result in severe hypoperistalsis caused by enteric neuropathy, mesenchymopathy, and myopathy. Notably, HSCR involving the small intestine, isolated hypoganglionosis, chronic idiopathic intestinal pseudo-obstruction, and megacystis-microcolon-intestinal hypoperistalsis syndrome carry a poor prognosis. Ultimately, small-bowel transplantation (SBTx) is necessary for refractory cases, but it is highly invasive and outcomes are less than optimal, despite advances in surgical techniques and management. Thus, regenerative therapy has come to light as...
Source: Surgery Today - September 5, 2023 Category: Surgery Source Type: research

Olverembatinib Treatment in Pediatric Patients With Relapsed Philadelphia-Chromosome-Positive Acute Lymphoblastic Leukemia
Clin Lymphoma Myeloma Leuk. 2023 May 11:S2152-2650(23)00140-4. doi: 10.1016/j.clml.2023.04.012. Online ahead of print.ABSTRACTTreatment outcomes for children with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) remained poor despite the use of intensive chemotherapy, imatinib or dasatinib, and consolidative allogeneic hematopoietic cell transplantation. Oleverembatinib, a third-generation ABL inhibitor, was found to be highly effective and safe in adults with chronic myeloid leukemia and in some adults with relapsed or refractory Ph+ ALL. We reviewed the efficacy and safety profile of olverembatin...
Source: Clinical Lymphoma and Myeloma - June 10, 2023 Category: Cancer & Oncology Authors: Xiaolan Li Jingliao Zhang Fang Liu Tianfeng Liu Ranran Zhang Yumei Chen Ye Guo Yongjun Fang Xiaojun Xu Ching-Hon Pui Xiaofan Zhu Source Type: research

Monitoring of strength, inflammation and muscle function in allogenic stem-cell transplantation patients – a pilot study for novel biomarker and risk stratification determination
ConclusionAllogeneic stem-cell transplantation is associated with immune system vulnerability due to conditioning, increased inflammation and fatigue, and loss of muscle strength and function. In addition to hsCRP, Kynurenine seems to be a reliable biomarker to monitor acute and regenerative inflammation status of alloSCT patients, while Musclin and Galectin-3 may be added to physiological assessment regarding myopathy and sarcopenia. Grip strength and daily activity level should be documented by professionals to identify risk patients early and support them with optimal (exercise) therapy.
Source: Frontiers in Immunology - May 15, 2023 Category: Allergy & Immunology Source Type: research

Gut-muscle axis and sepsis-induced myopathy: The potential role of gut microbiota
Biomed Pharmacother. 2023 May 6;163:114837. doi: 10.1016/j.biopha.2023.114837. Online ahead of print.ABSTRACTSepsis is described as an immune response disorder of the host to infection in which microorganisms play a non-negligible role. Most survivors of sepsis experience ICU-acquired weakness, also known as septic myopathy, characterized by skeletal muscle atrophy, weakness, and irreparable damage/regenerated or dysfunctional. The mechanism of sepsis-induced myopathy is currently unclear. It has been believed that this state is triggered by circulating pathogens and their related harmful factors, leading to impaired muscl...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - May 8, 2023 Category: Drugs & Pharmacology Authors: Yukun Liu Ligang Xu Zhaohui Yang Dongfang Wang Tianyu Li Fan Yang Zhanfei Li Xiangjun Bai Yuchang Wang Source Type: research

Transplantation Trends in End Stage Hypertrophic Cardiomyopathy Over 35 Years: A UNOS Registry Analysis
Hypertrophic cardiomyopathy (HCM) is a rare but potentially life-threatening form of hereditary myopathy with increasing incidence. Therapies are emerging for HCM but the incidence of end-stage HCM has been increasing. We sought to describe the incidence and outcomes of HCM transplantation over the last 35 years.
Source: The Journal of Heart and Lung Transplantation - April 1, 2023 Category: Transplant Surgery Authors: D.J. Miklin, E. DePasquale Tags: (527) Source Type: research

A Phase I Trial of SYK Inhibition with Fostamatinib in the Prevention and Treatment of Chronic Graft-Versus-Host Disease
Chronic graft-versus-host disease (cGVHD) is the most common cause of late morbidity and non-relapse mortality among patients who have undergone allogeneic hematopoietic stem cell transplantation (HCT).1 The presentation of cGVHD is highly heterogeneous and may involve multiple organ systems, often leading to detrimental impacts on quality of life and functional status.2,3 Standard first-line treatment involves prolonged systemic steroids, which can be complicated by numerous steroid-related toxicities including hyperglycemia, myopathy, and osteoporosis.
Source: Biology of Blood and Marrow Transplantation - December 24, 2022 Category: Hematology Authors: Chenyu Lin, Rachel A. DiCioccio, Tarek Haykal, William C. McManigle, Zhiguo Li, Sarah M. Anand, Jonathan C. Poe, Sonali J. Bracken, Wei Jia, Edwin P. Alyea, Adela R. Cardones, Taewoong Choi, Cristina Gasparetto, Michael R. Grunwald, Therese Hennig, Yubin Tags: AMA Source Type: research

Purtscher-like retinopathy in a patient with systemic tacrolimus vasculopathy
CONCLUSIONS: Purtscher-like retinopathy should be suspected in patients under treatment with calcineurin inhibitors especially in case of sudden and severe bilateral visual impairment.PMID:36451542 | DOI:10.1177/11206721221143157
Source: European Journal of Ophthalmology - December 1, 2022 Category: Opthalmology Authors: Alessandro Di Maggio Nila Volpi Davide Marigliani Guido Garosi Fabio Rollo Federica Ginanneschi Gian Marco Tosi Claudia Fabiani Source Type: research

Extracorporeal life support allows lung transplant in anti-MDA5+ rapidly progressive-interstitial lung disease.
Conclusions: The results provide crucial information for the management of anti-MDA5 RP-ILD. The bridge-to-recovery strategy in anti-MDA5 RP-ILD patients requiring ECLS despite specific prior treatment leads to undesirable results. In contrast, a bridge-to-emergency lung transplantation is not only feasible but also associated with a favorable outcome and appears therefore as the sole hope of survival.
Source: European Respiratory Journal - December 1, 2022 Category: Respiratory Medicine Authors: Bay, P., Pineton De Chambrun, M., Roux, A., Bunel, V., Combes, A., Israël Biet, D., Zuber, B., Nunes, H., Allenbach, Y., Uzunhan, Y. Tags: 02.01 - Acute critical care Source Type: research

Heart transplantation for COVID-19 myopathy in the United States
Evidence on characteristics and outcomes of patients undergoing heart transplantation for coronavirus disease 2019 (COVID-19) associated cardiomyopathy is limited to case reports. Of all 6332 patients aged ≥18 years undergoing heart transplant from July 2020 through May 2022 in the United Network for Organ Sharing database, 12 (0.2%) patients had COVID-19 myocarditis and 98 (1.6%) patients with the same level of care had non-COVID-19 myocarditis. Their median age was 49 (range 19-74) years. All pati ents were hospitalized in the intensive care unit and 92.7% (n=102) were on life support prior to transplantation.
Source: The Journal of Heart and Lung Transplantation - October 5, 2022 Category: Transplant Surgery Authors: George Gill, Amy Roach, Georgina Rowe, Dominic Emerson, Jon Kobashigawa, Errol P. Lobo, Fardad Esmailian, Michael E. Bowdish, Joanna Chikwe Tags: Brief Communication Source Type: research

Early cardiac rehabilitation after heart transplantation in a patient with limb-girdle muscular dystrophy: A case report
Rationale: Cardiac rehabilitation (CR) after heart transplantation (HT) decreases the mortality rate and increases exercise capacity of patients. Dilated cardiomyopathy develops in most patients with muscular dystrophy (MD), leading to advanced heart failure, necessitating the use of left ventricular assist devices or HT. As the clinical outcomes of left ventricular assist devices and HT in patients with myopathy differ from those in patients without myopathy, CR adapted to patients with MD should be considered. Patient concerns: A 39-year-old man with limb-girdle muscular dystrophy developed dilated cardiomyopa...
Source: Medicine - July 29, 2022 Category: Internal Medicine Tags: Research Article: Clinical Case Report Source Type: research

Extracorporeal life support allows lung transplant in anti-MDA5+ rapidly progressive interstitial lung disease
Anti-melanoma differentiation-associated gene 5 antibody (anti-MDA5) dermatomyositis (DM) is a rare subtype of idiopathic inflammatory myopathy, associated with severe interstitial lung disease (ILD) [1]. A subset of anti-MDA5 DM patients with rapidly progressive ILD (RP-ILD) have a very poor prognosis, with reported mortality rates reaching 80–84% [1, 2]. In this clinical setting, the use of extracorporeal life support (ECLS) is questionable, as reported in several studies that emphasise the futility of a bridge-to-recovery strategy [2, 3]. In this respect, emergency lung transplantation of previously unlisted patie...
Source: European Respiratory Journal - May 26, 2022 Category: Respiratory Medicine Authors: Bay, P., Pineton de Chambrun, M., Roux, A., Bunel, V., Combes, A., Israël-Biet, D., Zuber, B., Nunes, H., Allenbach, Y., Uzunhan, Y. Tags: Original Articles: Research letters Source Type: research